Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Inguinal Herniorrhaphy
Interventions: CPL-01, Naropin 150 MG Per 20 ML Injection, Placebo; Drug
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 2 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions: Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review; Radiation · Biological · Drug + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions: bortezomib, irinotecan hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: arsenic trioxide; Drug
Lead sponsor: Our Lady of Mercy Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
Interventions: Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Renal Impairment
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 58
States / cities: Birmingham, Alabama • Peoria, Arizona • Sierra Vista, Arizona + 55 more

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, paclitaxel, conventional surgery, neoadjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 2
States / cities: Chicago, Illinois • Columbus, Ohio

Conditions: HIV-associated Neuropathy, Polyneuropathy
Interventions: SAB378, methadone, SAB placebo, Methadone placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Diego, California • Brooklyn, New York • Rochester, New York

Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer
Interventions: Pembrolizumab, Cryoablation, Avelumab; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Bavituximab, Taxane; Biological · Drug
Lead sponsor: Peregrine Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Bakersfield, California • Tinley Park, Illinois

Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Interventions: Lintuzumab-Ac225, Venetoclax, Spironolactone; Biological · Drug
Lead sponsor: Actinium Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more

Conditions: Kidney Cancer
Interventions: gemcitabine hydrochloride, irinotecan hydrochloride; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Graft Vs Host Disease
Interventions: PRO 140, Placebo; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more

Conditions: Multiple Myeloma, Leukemia, Plasma Cell
Interventions: Carfilzomib, Melphalan, Filgrastim; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Papulopustular Rosacea
Interventions: omiganan, placebo; Drug
Lead sponsor: Maruho Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Santa Monica, California • New Haven, Connecticut + 14 more

Conditions: Non-small Cell Lung Cancer
Interventions: Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin; Drug
Lead sponsor: Optimum Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Richmond, Virginia

Conditions: Acute Myelogenous Leukemia
Interventions: DC/AML Fusion Vaccine, Observation; Biological · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Madison, Wisconsin

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more

Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Interventions: Osimertinib, Cyclosporine A (CsA), ctDNA Biopsy Panel; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain Cancer
Interventions: Dacomitinib; Drug
Lead sponsor: David Piccioni, M.D., Ph.D; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Ovarian Neoplasm
Interventions: Cyclophosphamide, Paclitaxel, Cisplatin, G-CSF; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Kidney Cancer, Lung Cancer, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, flow cytometry, immunoenzyme technique, biopsy, cryosurgery; Biological · Other · Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Renal Cell Carcinoma
Interventions: Neoadjuvant Lenvatinib, Neoadjuvant Pembrolizumab, Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection, Adjuvant Pembrolizumab; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Age Related Macular Degeneration
Interventions: 0.5 mg ranibizumab, 3 mg PF-04523655, 1 mg PF-04523655; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: San Francisco, California • Fort Myers, Florida • Winter Haven, Florida + 4 more

Search by objective public record fields.

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Venetoclax and Lintuzumab-Ac225 in AML Patients

Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

A Twelve Week Safety and Efficacy Study in Rosacea

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC

A Phase II Study of Dacomitinib in Progressive Brain Metastases

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).